Parimer | Parimer Scientific

The CDMO company designs, develops, and manufactures new chemical entities to treat human disease. Our cGMP suites support startups to global enterprises across clinical and commercial API production. Scientist-led and regulatory-savvy, we guide you through IND, CMC, ICH, FDA, and ISO challenges.

The company is an independent, American-owned, and operated private scientific service laboratory that was started in 2018. Today, the company is best classified as a Drug Substance CDMO that supports dozens of clients in their efforts to get new molecules and treatments to those in need.

The company has no shareholders, private equity interests, or other profit-driven parties beyond the chemists and engineers employed in the company´s operations. This organizational structure allows the company to remain highly competitive against more corporate and executive-heavy competitors.